Merck has terminated a Phase 2 Alzheimer’s trial testing oral candidate MK-1167, citing underwhelming results in an interim analysis. The decision marks another setback for Neuphoria Therapeutics, the partner behind the asset, and adds to the risk profile for small-molecule Alzheimer’s programs. The report says Merck ended the mid-stage study after interim performance failed to meet expectations. The move underscores how quickly assets can lose funding and attention if interim endpoints do not demonstrate clinically actionable signals. For drug developers and investors, the termination is a reminder that Alzheimer’s trials continue to be high bar for efficacy and that adaptive decision-making at interim stages can abruptly change partner economics and development timelines. The discontinuation also intensifies competitive pressure for remaining Alzheimer’s programs, particularly those advancing through mid-stage readouts.